Bliss GVS Pharma Appoints Santosh Parab as Director, Rahul Adakmol as CEO
Bliss GVS Pharma appointed Mr. Santosh Parab as Non-Executive Non-Independent Director effective July 03, 2026. Mr. Rahul Adakmol will be the new CEO from July 15, 2026. Mr. Narsimha Shibroor Kamath steps down as CEO on July 14, 2026, continuing as MD.
The appointment of a new CEO and a new director can have a medium-term impact on the company's strategic direction and operational execution. The continuity of the Managing Director mitigates some of the potential disruption.
The announcement details routine management and board changes, including appointments and a CEO stepping down while remaining MD. There are no immediate financial implications or significant strategic shifts highlighted that would strongly sway sentiment.
Bliss GVS Pharma Limited announced significant board and management changes following a meeting held on July 03, 2026. The Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, has approved the appointment of Mr. Santosh Parab (DIN:01622988) as an Additional Director in the capacity of Non-Executive Non-Independent Director, effective July 03, 2026.
Mr. Parab is a qualified Chartered Accountant with over 35 years of experience in audit, taxation, corporate finance, valuation, mergers and acquisitions, restructuring, and financial management. His expertise spans business valuations, due diligence, financial restructuring, and corporate advisory services, having worked with leading financial institutions and organizations.
Furthermore, the company has appointed Mr. Rahul Adakmol as the Chief Executive Officer of the Company, with effect from July 15, 2026. Mr. Adakmol, an MBA from IIM Bangalore and a Chemical Engineering graduate from UDCT, brings over 22 years of experience across the value chain, including sales, marketing, manufacturing, supply chain, and strategy, with a proven track record in scaling high-growth businesses and leading strategic initiatives.
Concurrently, Mr. Narsimha Shibroor Kamath will step down from his position as Chief Executive Officer, with effect from the close of business hours on July 14, 2026. He will continue to serve the company in his role as Managing Director.
What to do with a filing like this
Bliss GVS Pharma Limited filed this with the NSE as a statutory disclosure, categorised under board changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bliss GVS Pharma Limited. Read the original for the full detail.